fda warning bpc-157 peptide products – Research FDA's Overreach on Compounded Peptides
Description
Modulation of NAD + biosynthesis The salvage and de novo synthesis pathways of NAD + are also potential targets for therapies boosting NAD + levels in vivo
It is a good appetite stimulant and this is the reason why it helps growth
Compounded medications such as MIC + B12 are not FDA approved
However, because it influences metabolic pathways, its essential to approach its use cautiously
